Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs.
Bedinvetmab (0.5-1 mg/kg; s.c. for 28 d) alleviates the pain associated with canine osteoarthritis[1].
Bedinvetmab (1 mg/kg; s.c. monthly; 3× and 10× dose multiples) is well tolerated in normal laboratory Beagle dogs for 6 months and with 2 weeks' concurrent NSAID administration[2].
References:
[1]. Corral MJ, et, al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021 Nov;48(6):943-955.
[2]. Krautmann M, et, al. Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. Vet J. 2021 Oct;276:105733.